Results 11 to 20 of about 358,941 (349)

Isocitrate dehydrogenase inhibitors in acute myeloid leukemia

Biomarker Research, 2019
Isocitrate dehydrogenase (IDH) is a key enzyme involved in the conversion of isocitrate to α-ketoglutarate (α-KG) in the tricarboxylic acid (TCA) cycle. IDH mutation produces a neomorphic enzyme, which can lead to the abnormal accumulation of R-2-HG and ...
Xiaoyan Liu, Yuping Gong
doaj   +2 more sources

Mutant Isocitrate Dehydrogenase Inhibitors as Targeted Cancer Therapeutics

Frontiers in Oncology, 2019
The identification of heterozygous neomorphic isocitrate dehydrogenase (IDH) mutations across multiple cancer types including both solid and hematologic malignancies has revolutionized our understanding of oncogenesis in these malignancies and the ...
Danielle Golub, Danielle Golub, Nishanth Iyengar, Siddhant Dogra, Taylor Wong, Devin Bready, Karen Tang, Karen Tang, Aram S. Modrek, Dimitris G. Placantonakis, Dimitris G. Placantonakis, Dimitris G. Placantonakis, Dimitris G. Placantonakis, Dimitris G. Placantonakis   +13 more
doaj   +2 more sources

Isocitrate dehydrogenase mutations in myeloid malignancies [PDF]

Leukemia, 2016
Alterations to genes involved in cellular metabolism and epigenetic regulation are implicated in the pathogenesis of myeloid malignancies. Recurring mutations in isocitrate dehydrogenase (IDH) genes are detected in approximately 20% of adult patients with acute myeloid leukemia (AML) and 5% of adults with myelodysplastic syndromes (MDS).
Medeiros, B C, Fathi, A T, DiNardo, C D, Pollyea, D A, Chan, S M, Swords, R   +5 more
openaire   +4 more sources

Isocitrate protects DJ-1 null dopaminergic cells from oxidative stress through NADP+-dependent isocitrate dehydrogenase (IDH). [PDF]

PLoS Genetics, 2017
DJ-1 is one of the causative genes for early onset familiar Parkinson's disease (PD) and is also considered to influence the pathogenesis of sporadic PD. DJ-1 has various physiological functions which converge on controlling intracellular reactive oxygen
Jinsung Yang, Min Ju Kim, Woongchang Yoon, Eun Young Kim, Hyunjin Kim, Yoonjeong Lee, Boram Min, Kyung Shin Kang, Jin H Son, Hwan Tae Park, Jongkyeong Chung, Hyongjong Koh   +11 more
doaj   +2 more sources

Wild-Type Isocitrate Dehydrogenase-Dependent Oxidative Decarboxylation and Reductive Carboxylation in Cancer and Their Clinical Significance

Cancers, 2022
Simple Summary While isocitrate dehydrogenases have been known for decades, their mechanisms in tumors are gradually becoming clearer. The three isocitrate dehydrogenase isoforms in human cells differ in their subcellular localization, molecular ...
Q. He, Junxiong Chen, Zijing Xie, Zhenzhou Chen   +3 more
semanticscholar   +1 more source

Wild-type isocitrate dehydrogenase under the spotlight in glioblastoma

Oncogene, 2021
Brain tumors actively reprogram their cellular metabolism to survive and proliferate, thus offering potential therapeutic opportunities. Over the past decade, extensive research has been done on mutant IDH enzymes as markers of good prognosis in ...
Gabriel Alzial, Ophélie Renoult, F. Paris, C. Gratas, A. Clavreul, C. Pecqueur   +5 more
semanticscholar   +1 more source

Ivosidenib in Isocitrate Dehydrogenase 1–Mutated Advanced Glioma

Journal of Clinical Oncology, 2020
PURPOSE Diffuse gliomas are malignant brain tumors that include lower-grade gliomas (LGGs) and glioblastomas. Transformation of low-grade glioma into a higher tumor grade is typically associated with contrast enhancement on magnetic resonance imaging ...
I. Mellinghoff, B. Ellingson, M. Touat, E. Maher, M. I. de la Fuente, M. Holdhoff, G. Cote, H. Burris, F. Janku, R. Young, Raymond Y Huang, Liewen Jiang, S. Choe, Bin Fan, K. Yen, Min Lu, C. Bowden, L. Steelman, S. Pandya, T. Cloughesy, P. Wen   +20 more
semanticscholar   +1 more source

Isocitrate dehydrogenase (IDH) status prediction in histopathology images of gliomas using deep learning

Scientific Reports, 2020
Mutations in isocitrate dehydrogenase genes IDH1 and IDH2 are frequently found in diffuse and anaplastic astrocytic and oligodendroglial tumours as well as in secondary glioblastomas.
Sidong Liu, Zubair Shah, A. Sav, C. Russo, S. Berkovsky, Y. Qian, E. Coiera, A. Di Ieva   +7 more
semanticscholar   +1 more source

Biochemical adaptation of Weigela florida «Variegata» Bunge A. D. C. microclones to salt- and copper induced stress [PDF]

Сибирский лесной журнал, 2017
Microclones of perennial shrub Weigela florida «Variegata» were prepared, adapted to the conditions of salinity and increased copper ions proportion during the three-step in vitro experiment.
O. A. Zemlyanukhina, V. N. Kalaev, V. S. Voronina, A. T. Eprintsev   +3 more
doaj   +1 more source

Mutant Isocitrate Dehydrogenase 1 Inhibitor Ivosidenib in Combination With Azacitidine for Newly Diagnosed Acute Myeloid Leukemia

Journal of Clinical Oncology, 2020
PURPOSE Ivosidenib is an oral inhibitor of the mutant isocitrate dehydrogenase 1 (IDH1) enzyme, approved for treatment of IDH1-mutant (mIDH1) acute myeloid leukemia (AML).
C. Dinardo, A. Stein, E. Stein, A. Fathi, O. Frankfurt, A. Schuh, H. Döhner, G. Martinelli, P. Patel, E. Raffoux, P. Tan, A. Zeidan, S. de Botton, H. Kantarjian, R. Stone, M. Frattini, F. Lersch, J. Gong, D. Gianolio, V. Zhang, A. Franovic, Bin Fan, M. Goldwasser, S. Daigle, S. Choe, Bin Wu, T. Winkler, P. Vyas   +27 more
semanticscholar   +1 more source